Cargando…

A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple‐negative breast cancer

BACKGROUND: Patients with metastatic triple‐negative breast cancer (mTNBC) frequently experience brain metastasis. This study aimed to identify prognostic factors and construct a nomogram for predicting brain metastasis possibility and brain screening benefit in mTNBC patients. METHODS: Patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Mingxi, Jin, Yizi, Jin, Jia, Wang, Biyun, Hu, Xichun, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666757/ https://www.ncbi.nlm.nih.gov/pubmed/32945619 http://dx.doi.org/10.1002/cam4.3449

Ejemplares similares

Heterogeneity derived from (18)F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients
por: Xie, Yizhao, et al.
Publicado: (2022)

Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer
por: Jin, Jia, et al.
Publicado: (2018)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2021)

Identification of Key Genes Associated with Brain Metastasis from Breast Cancer: A Bioinformatics Analysis
por: Zeng, Cheng, et al.
Publicado: (2022)

Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
por: Lin, Ying, et al.
Publicado: (2020)

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients
por: Wang, Biyun, et al.
Publicado: (2022)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
por: Mougalian, Sarah S., et al.
Publicado: (2018)

Impact of histotypes on preferential organ‐specific metastasis in triple‐negative breast cancer
por: Li, Yaming, et al.
Publicado: (2019)

Value of screening and follow‐up brain MRI scans in patients with metastatic melanoma
por: Eggen, Annemarie C., et al.
Publicado: (2021)

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer
por: Zhao, Yannan, et al.
Publicado: (2020)

Radiotherapy after surgery has significant survival benefits for patients with triple‐negative breast cancer
por: Yao, Yi, et al.
Publicado: (2019)

The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis
por: Zhang, Haomeng, et al.
Publicado: (2021)

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
por: Hu, Xichun, et al.
Publicado: (2014)

Development and validation of a nomogram for predicting overall survival of patients with cancer of unknown primary: a real-world data analysis
por: Jin, Yizi, et al.
Publicado: (2021)

Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis
por: Weichhaus, Michael, et al.
Publicado: (2014)

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
por: Brown, Landon C., et al.
Publicado: (2021)

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
por: Gong, Chengcheng, et al.
Publicado: (2017)

Operative and peri‐operative considerations in the management of brain metastasis
por: Sankey, Eric W., et al.
Publicado: (2019)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma
por: He, MinKe, et al.
Publicado: (2019)

Prognosis in triple‐negative apocrine carcinomas of the breast: A population‐based study
por: Wu, Wenyu, et al.
Publicado: (2019)

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method
por: Xie, Yizhao, et al.
Publicado: (2019)

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
por: Shabto, Julie M., et al.
Publicado: (2020)

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
por: Cao, Jun, et al.
Publicado: (2022)

OSW‐1 inhibits tumor growth and metastasis by NFATc2 on triple‐negative breast cancer
por: Ding, Xiaorong, et al.
Publicado: (2020)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

LIPG signaling promotes tumor initiation and metastasis of human basal-like triple-negative breast cancer
por: Lo, Pang-Kuo, et al.
Publicado: (2018)

An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer
por: Jia, Zhenya, et al.
Publicado: (2018)

Genomic stratification beyond Ras/B‐Raf in colorectal liver metastasis patients treated with hepatic arterial infusion
por: Smith, J. Joshua, et al.
Publicado: (2019)

Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers
por: Abd El-Aziz, Yomna S., et al.
Publicado: (2021)

Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
por: Liu, Chang, et al.
Publicado: (2020)

Development and characterization of two human triple‐negative breast cancer cell lines with highly tumorigenic and metastatic capabilities
por: Su, Yanrong, et al.
Publicado: (2016)

Patient expectations of benefit from systemic treatments for metastatic prostate cancer
por: Oswald, Laura B., et al.
Publicado: (2019)

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis
por: Xie, Yizhao, et al.
Publicado: (2022)

Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER‐based study
por: Qiu, Miao‐Zhen, et al.
Publicado: (2018)

Prospective memory impairment following whole brain radiotherapy in patients with metastatic brain cancer
por: Cheng, Huaidong, et al.
Publicado: (2018)

Emerging findings into molecular mechanism of brain metastasis
por: Ni, Wenting, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u0dk149a6n2kq21ff9p5m40to9